NeoNeuro SAS  is pleased to announce a collaboration with the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL)  group. The collaboration is focused on exploring the potential of an innovative diagnostic platform developed by NeoNeuro called Aptamarkers, for the diagnosis of Alzheimer’s disease in blood serum. NeoNeuro, a subsidiary of the Canadian aptamer company, NeoVentures Biotechnology Inc. developed this platform within the IPEPs incubator at ICM in Paris. The platform provides deep fingerprints of pathology specific epitopes on a real time, quantitative basis. This research has potential to enable a biochemical basis to characterize the effect of Alzheimer’s disease on a personalized basis. Results from an initial pilot study on 100 samples are expected by the fall of 2017.